TY - JOUR
TI - The Use of Platelet-rich Plasma as a Novel Nonsurgical Treatment of the
Female Stress Urinary Incontinence: A Prospective Pilot Study
AU - Athanasiou, Stavros
AU - Kalantzis, Christos
AU - Zacharakis, Dimitrios
AU - and Kathopoulis, Nikolaos
AU - Pontikaki, Artemis
AU - Grigoriadis,
AU - Themistoklis
JO - FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY
PY - 2021
VL - 27
TODO - 11
SP - E668-E672
PB - Lippincott, Williams & Wilkins
SN - null
TODO - 10.1097/SPV.0000000000001100
TODO - PRP; stress urinary incontinence; minimally invasive treatment; female
incontinence
TODO - Objectives The aim of the study was to evaluate the efficacy and safety
of platelet-rich plasma (PRP) for the treatment of stress urinary
incontinence (SUI). Methods This was a prospective observational pilot
study conducted in a tertiary referral unit, enrolling women with SUI
booked for SUI surgery. A total of 20 consecutive women met the
inclusion criteria and attended all follow-ups. All participants
underwent 2 PRP injections into the lower one third of the anterior
vaginal wall at 4- to 6-week intervals. At baseline, they underwent
urodynamic studies, a 1-hour pad test, and completed the International
Consultation on Incontinence Questionnaire-Female Lower Urinary Tract
Symptoms and King’s Health Questionnaire. At follow-up visits (1, 3, and
6 months), patients underwent the 1-hour pad test and completed the
King’s Health Questionnaire, International Consultation on Incontinence
Questionnaire-Female Lower Urinary Tract Symptoms, and Patient Global
Impression Scale of Improvement. Primary outcome was to evaluate
posttreatment SUI. Secondary outcomes included assessment of
patient-reported questionnaires, assessment of urine loss (1-hour pad
test), and the level of discomfort during injections (visual analog
scale score). Statistical analysis was performed before PRP and 1, 3,
and 6 months after the last treatment. Results A significant improvement
in SUI symptoms was observed 3 months after treatment with a further
improvement at 6 months. A mean reduction of 50.2% in urine loss was
observed in the 1-hour pad test. At the 6-month follow-up, 80.0% of
women reported to be at least improved. No adverse effects were
observed. Conclusions Platelet-rich plasma injections were both
effective and safe at least in the short term and could be offered as an
alternative outpatient procedure for the treatment of SUI. However,
these encouraging findings warrant further investigation with randomized
controlled trials.
ER -